刘启发，南方医科大学血液病研究院院长、血液病研究所所长；南方医院终身教授、血液科学术带头人；教授、主任医师、博士生导师。亚太地区血液学会委员，中华医学会血液学分会副主任委员，中华医学会血液学分会感染学组组长，中国老年医学会血液学分会副会长，中国研究型医院学会细胞研究与治疗分会副主任委员，中国医师协会血液医师分会常委；广东省医学会血液学分会主任委员和细胞治疗学会副主任委员；广东省血液肿瘤首席专家。从1983年大学毕业后一直从事血液肿瘤的诊疗和相关基础研究工作，曾在日本东京自治医科大学作为客座研究员进行白血病分子生物学研究工作。在白血病的分子发病机理、肿瘤免疫治疗、造血干细胞移植和免疫功能低下人群感染防治等领域做出较大成绩。曾先后主持3项国家重点研发计划，3项863计划，10项国家自然科学包括重点项目1项和20余项省部级课题的研究。相关研究成果获国家科技进步二等奖1项、省部级科技成果一等奖3项和二等奖5项。在国内外核心期刊发表论文300余篇包括：Lancet Oncology, JCO, Lancet Haematology, STTT, PNAS, Blood 和Leukemia等SCI期刊250余篇。

造血干细胞移植与恶性血液病诊治

科研立项：

1. 国家自然科学基金重大项目，造血干细胞移植后免疫稳态重塑与抗宿主病发生及其干预，82293634，2023.01-2027.12，275万元，在研，主持。

2. 国家重点研发计划项目，聚焦新靶点研发难治复发AML的新策略，2021YFC2500302，2021.12-2024.11，624万元，在研，子课题负责人。

3. 国家重点研发计划项目，MSC治疗移植物抗宿主病等重大疾病的监管和评价体系研究，2022YFA1105003，2022.07-2027.11，400万元，在研，课题骨干。

4. 国家自然科学基金面上项目，MSC-ILC-TEC轴在allo-HSCT受体胸腺组织结构重塑和功能改善中的作用及机理研究，81970161，2020.1-2023.12，57万元，已结题，主持。

5. 广东省重点研发计划项目，间充质干细胞防治异基因造血干细胞移植后移植物抗宿主病的临床及机理研究，2019B020236004，2019.1-2021.12，500万元，已结题，主持。

6. 国家重点研发计划项目,不同来源间充质干细胞防治异基因造血干细胞移植后移植物抗宿主病的临床优化方案及机理研究, 2017YFA0105500,2017.7-2021.12，1657万元，已结题，主持。

代表性论文：

1.Xuan L^#, Wang Y^#, Huang F^#, Fan Z^#, Xu Y, Sun J, Xu N, Deng L, Li X, Liang X, Luo X, Shi P, Liu H, Wang Z, Jiang L, Yu C, Zhou X, Lin R, Chen Y, Tu S, Huang X, Liu Q*. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020;21(9):1201-1212.

2.Ling Y^#, Xuan L^#, Xu N^#, Huang F^#, Fan Z^#, Guo Z, Xu X, Liu H, Lin R, Yu S, Zhang H, Jin H, Wu M, Liu C, Liang X, Ou R, Zhang Y, Liu X, Qu H, Zhai X, Sun J, Zhao Y, Liu Q*. Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial. J Clin Oncol. 2023 Oct 10;41(29):4632-4642.

3.Zhang H^#, Fan Z^#, Huang F^#, Han L^#, Xu Y, Xu N, Deng L, Wang S, Lin D, Luo X, Zhang Q, Liu X, Li X, Liang X, Xie S, Qu H, Yu S, Zhou H, Shi P, Xuan L, Lin R, Liu H, Jin H, Sun J, Liu Q*. Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial. J Clin Oncol. 2023 Jan 10;41(2):343-353. 

4.Xuan L^#, Dai M^#, Jiang E^#, Wang Y^#, Huang F^#, Fan Z, Xu N, Nie D, Liang X, Chen H, Ye J, Shi P, Liu H, Jin H, Lin R, Yan C, Zhang Y, Sun J, Han M, Liu Q*. The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2023;10(3):e178-e190. 

5.Xuan L^#, Wang Y^#, Yang K^#, Shao R^#, Huang F^#, Fan Z, Chi P, Xu Y, Xu N, Deng L, Li X, Liang X, Luo X, Shi P, Liu H, Wang Z, Jiang L, Lin R, Chen Y, Tu S, Zhang Y, Sun J, Huang X, Liu Q*. Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2023 Aug;10(8):e600-e611.

6.Shao R^#, Zhang Y^#, He J^#, Huang F^#, Fan Z^#, Yang K, Xu Y, Xu N, Luo Y, Deng L, Zhang X, Chen J, Han M, Li X, Yu S, Liu H, Liang X, Luo X, Shi P, Wang Z, Jiang L, Zhou X, Lin R, Chen Y, Tu S, Sun J, Wang Y*, Liu Q*, Xuan L*. Impact of genetic patterns on sorafenib efficacy in patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: a multi-center, cohort study. Signal Transduct Target Ther. 2023 Sep 14;8(1):348.

7.Zhao K#, Lin R#, Fan Z#, Chen X#, Wang Y#, Huang F, Xu N, Zhang X, Zhang X, Xuan L, Wang S, Lin D, Deng L, Nie D, Weng J, Li Y, Zhang X, Li Y, Xiang AP*, Liu Q*. Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial. J Hematol Oncol. 2022 Mar 7;15(1):22.

8.Yu S^#, Huang F^#, Wang Y^#, Xu Y, Yang T, Fan Z, Lin R, Xu N, Xuan L, Ye J, Yu W, Sun J, Huang X*, Liu Q*. Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study. Leukemia. 2020;34(5):1433-1443.

9. Liu H^#, Xuan L^#, Lin R^#, Deng L^#, Fan Z, Nie D, Li X, Liang X, Xu D, Zhang Y, Xu N, Ye J, Jin H, Lin D, Ma L, Sun J, Huang F^*, Liu Q^*. A new pre-emptive TKIs strategy for preventing relapse based on BCR/ABL monitoring for Ph+ALL undergoing allo-HCT: a prospective clinical cohort study. Leukemia. 2021; 35(7):2054-2063.

10. Yu S, Fan Z, Ma L, Wang Y, Huang F, Zhang Q, Huang J, Wang S, Xu N, Xuan L, Xiong M, Han L, Sun Z, Zhang H, Liu H, Yu G, Shi P, Xu J, Wu M, Guo Z, Xiong Y, Duan C, Sun J, Liu Q*, Zhang Y*. Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes. JAMA Netw Open. 2021;4(7): e2115991.

11. Xuan L, Liu Q^*. Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. J Hematol Oncol. 2021; 14(1):4.

12. Yu S, Huang F, Fan Z, Xuan L, Nie D, Xu Y, Yang T, Wang S, Jiang Z, Xu N, Lin R, Ye J, Lin D, Sun J, Huang X, Wang Y*, Liu Q*. Haploidentical versus HLA-matched sibling transplantation for refractory acute leukemia undergoing sequential intensified conditioning followed by DLI: an analysis from two prospective data. J Hematol Oncol. 2020;13(1):18.

13.Qin A^#, Lai DH^#, Liu Q^#, Huang W^#, Wu YP, Chen X, Yan S, Xia H, Hide G, Lun ZR*, Ayala FJ*, Xiang AP*. Guanylate-binding protein 1 (GBP1) contributes to the immunity of human mesenchymal stromal cells against Toxoplasma gondii. Proc Natl Acad Sci U S A. 2017;114(6):1365-1370.

14. Jin H^#, Ni X, Deng R, Song Q, Young J, Cassady K, Zhang M, Forman S, Martin PJ, Liu Q*, Zeng D*. Antibodies from donor B cells perpetuate cutaneous chronic graft-versus-host disease in mice. Blood. 2016;127(18):2249-60.